For the year ending 2025-12-31, ABT made $44,328M in revenue. $6,524M in net income. Net profit margin of 14.72%.
| Income Statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Net sales | 44,328 | 41,950 | 40,109 | 43,653 |
| Cost of products sold, excluding amortization of intangible assets | 19,319 | 18,706 | 17,975 | 19,142 |
| Amortization of intangible assets | 1,682 | 1,878 | 1,966 | 2,013 |
| Research and development | 2,942 | 2,844 | 2,741 | 2,888 |
| Selling, general and administrative | 12,332 | 11,697 | 10,949 | 11,248 |
| Total operating cost and expenses | 36,275 | 35,125 | 33,631 | 35,291 |
| Operating earnings | 8,053 | 6,825 | 6,478 | 8,362 |
| Interest expense | 493 | 559 | 637 | 558 |
| Interest income | 308 | 344 | 385 | 183 |
| Net foreign exchange (gain) loss | 50 | 27 | -41 | -2 |
| Other (income) expense, net | 548 | 376 | 479 | 321 |
| Earnings before taxes | 8,466 | 7,013 | 6,664 | 8,306 |
| Taxes on earnings | 1,942 | -6,389 | 941 | 1,373 |
| Earnings from continuing operations | - | - | - | 6,933 |
| Net earnings from discontinued operations, net of taxes | - | - | - | 0 |
| Net earnings | 6,524 | 13,402 | 5,723 | 6,933 |
| Basic EPS | 3.73 | 7.67 | 3.28 | 3.94 |
| Diluted EPS | 3.72 | 7.64 | 3.26 | 3.91 |
| Basic Average Shares | 1,741,000,000 | 1,740,000,000 | 1,740,000,000 | 1,753,000,000 |
| Diluted Average Shares | 1,748,000,000 | 1,748,000,000 | 1,749,000,000 | 1,764,000,000 |
ABBOTT LABORATORIES (ABT)
ABBOTT LABORATORIES (ABT)